Literature DB >> 17503125

Cognitive screening in multiple sclerosis.

Peter Scherer1.   

Abstract

Cognitive screening tests in multiple sclerosis (MS) are time- and cost-saving test instruments. In the case of a positive test result (alert function) a comprehensive cognitive test procedure should be administered. This paper explains what cognitive screening in MS means and presents several screening instruments used in MS with their statistical test characteristics, e. g. sensitivity and specificity.

Entities:  

Mesh：

Year:  2007        PMID： 17503125     DOI： 10.1007/s00415-007-2008-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  20 in total

1.  The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis.

Authors:  T Swirsky-Sacchetti; H L Field; D R Mitchell; J Seward; F D Lublin; R L Knobler; C F Gonzalez
Journal:  J Clin Psychol       Date:  1992-11

2.  Identification and management of cognitive disorders in multiple sclerosis--a consensus approach.

Authors:  Eckart Lensch; Mike Matzke; Hela-Felicitas Petereit; Peter Scherer; Stefan Schramm; Pasquale Calabrese
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

3.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

Review 4.  How to read a paper. Papers that report diagnostic or screening tests.

Authors:  T Greenhalgh
Journal:  BMJ       Date:  1997-08-30

5.  Paced auditory serial-addition task: a measure of recovery from concussion.

Authors:  D M Gronwall
Journal:  Percept Mot Skills       Date:  1977-04

6.  The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study.

Authors:  P Scherer; I K Penner; A Rohr; H Boldt; I Ringel; H Wilke-Burger; E Burger-Deinerth; K Isakowitsch; M Zimmermann; S Zahrnt; R Hauser; K Hilbert; K Tiel-Wilck; K Anvari; A Behringer; I Peglau; H Friedrich; A Plenio; G Benesch; R Ehret; I Nippert; G Finke; I Schulz; B Bergtholdt; S Breitkopf; P Kaskel; F Reischies; J Kugler
Journal:  Mult Scler       Date:  2007-01-29       Impact factor: 6.312

7.  Reliable screening for neuropsychological impairment in multiple sclerosis.

Authors:  Ralph H B Benedict; Darcy Cox; Laetitia L Thompson; Fred Foley; Bianca Weinstock-Guttman; Frederick Munschauer
Journal:  Mult Scler       Date:  2004-12       Impact factor: 6.312

8.  The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples.

Authors:  Michael C Diehr; Mariana Cherner; Tanya J Wolfson; S Walden Miller; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2003-06       Impact factor: 2.475

9.  Screening for cognitive dysfunction in multiple sclerosis.

Authors:  M R Basso; S Beason-Hazen; J Lynn; K Rammohan; R A Bornstein
Journal:  Arch Neurol       Date:  1996-10

10.  Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI).

Authors:  W W Beatty; R H Paul; S L Wilbanks; K A Hames; C R Blanco; D E Goodkin
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910
View more
  3 in total

Review 1.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

2.  Assessment of early cognitive impairment in patients with clinically isolated syndromes and multiple sclerosis.

Authors:  Leyla Baysal Kıraç; Özgül Ekmekçi; Nur Yüceyar; Ayşe Sağduyu Kocaman
Journal:  Behav Neurol       Date:  2014-04-14       Impact factor: 3.342

Review 3.  Cognitive impairment in multiple sclerosis: diagnosis and monitoring.

Authors:  Virginia Meca-Lallana; Francisco Gascón-Giménez; Ricardo C Ginestal-López; Yolanda Higueras; Nieves Téllez-Lara; Joan Carreres-Polo; Sara Eichau-Madueño; Jesús Romero-Imbroda; Ángela Vidal-Jordana; Francisco Pérez-Miralles
Journal:  Neurol Sci       Date:  2021-04-01       Impact factor: 3.307
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.